



GP 1636

PATENT
#6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Fallaux et al.

Serial No.: 09/356,575

Filed: July 19, 1999

For: PACKAGING SYSTEMS FOR
HUMAN RECOMBINANT ADENOVIRUS
TO BE USED IN GENE THERAPY

Examiner: To be assigned

Group Art Unit: 1636

Attorney Docket No.: 3935US

CERTIFICATE OF MAILING

I hereby certify that this paper or fee along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail (under 37 C.F.R. § 1.8(a)) on the date of deposit shown below with sufficient postage and in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

March 31, 2000
Date of Deposit

Lynette Eliason
Signature of registered practitioner or other person
having reasonable basis to expect mailing to occur on
date of deposit shown pursuant to 37 C.F.R. §
1.8(a)(1)(ii)

Lynette Eliason
Typed/printed name of person whose signature is
contained above

APR 07 2000

TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as

defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56(b) exists.

DOCUMENTS

U.S. Patent Documents

U.S. Patent No.	Issue Date	Inventor
4,405,712	09/20/83	Vande Woude et al.
4,497,796	02/05/85	Salser et al.
4,727,028	02/23/88	Santerre et al.
4,740,463	04/26/88	Weinberg et al.
5,190,931	03/02/93	Inouye
5,208,149	05/04/93	Inouye
5,518,913	05/21/96	Massie et al.
5,837,511	11/17/98	Falck-Pedersen et al.
5,994,106	11/30/99	Kovesdi et al.
5,994,128	11/30/99	Fallaux et al.
6,033,908	03/07/00	Bout et al.
6,040,174	03/21/00	Imler et al.

APR 07 2000
TECH CENTER 1600/2900

Foreign Patent Documents

<u>Document No.</u>	<u>Date</u>	<u>Country</u>
CA 2053187	04/11/93	Canada
WO 94/28152	12/08/94	PCT
FR 2707664	01/20/95	France
WO 95/02697	01/26/95	PCT
CA 2117668	09/10/95	Canada
AU-A-28533/95	03/21/96	Australia

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56 & 1.175, applicant hereby identifies the following listed copending applications naming the same inventor(s):

Serial No.: 09/214,836

Filed: October 4, 1999

For: MELANOMA ASSOCIATED PEPTIDE ANALOGUES AND VACCINES
AGAINST MELANOMA

Serial No.: 09/444,284

Filed: November 19, 1999

For: GENE DELIVERY VECTORS PROVIDED WITH A TISSUE TROPISM FOR
SMOOTH MUSCLE CELLS, AND/OR ENDOTHELIAL CELLS

Serial No.: 09/381,716

Filed: January 4, 2000

For: METHODS AND COMPOSITIONS FOR GENETICALLY MODIFYING
PRIMATE BONE MARROW CELLS

Serial No.: 09/481,201

Filed: January 11, 2000

For: INTERLEUKIN-3 GENE THERAPY FOR CANCER

Serial No.: 09/502,624

Filed: February 11, 2000

For: VECTORS AND METHODS FOR PROVIDING CELLS WITH ADDITIONAL
NUCLEIC ACID MATERIAL INTEGRATED IN THE GENOME OF SAID
CELLS

Serial No.: 09/506,548

Filed: February 17, 2000

For: PACKAGING SYSTEMS FOR HUMAN RECOMBINANT ADENOVIRUS TO
BE USED IN GENE THERAPY


Serial No.: 09/517,898

Filed: March 3, 2000

For: MEANS AND METHODS FOR FIBROBLAST-LIKE OR MACROPHAGE-
LIKE CELL TRANSFUSION

This Information Disclosure Statement is believed to be filed before the mailing date of a first Office Action, and no certification pursuant to 37 C.F.R. § 1.97(c) or a fee pursuant to 37 C.F.R. § 1.17(p) is required. In the event that a first office action has been mailed, the office is authorized to charge the requisite fee from account no. 20-1469.

Respectfully submitted,



Allen C. Turner

Registration No. 33,041

Attorney for Applicants

TRASK, BRITT & ROSSA

P. O. Box 2550

Salt Lake City, Utah 84110-2550

Telephone: (801) 532-1922

Date: March 31, 2000

ACT/le

Enclosure: Copy of documents cited
Form PTO-1449